Avila Therapeutics, Inc.

Michael Gilman didn't have much time to enjoy "retirement" after Bristol-Myers Squibb Co. acquired his last company Padlock Therapeutics Inc. for up to $600m. Within months he was immersed in

“How much things can change for a biotech company in just 12 months,” Clovis Oncology Inc. ’s Chief Financial Officer Erle Mast mused at the Credit Suisse Healthcare conference on Nov. 12, referrin

“How much things can change for a biotech company in just twelve months,” mused Clovis Oncology Inc. ’s Chief Financial Officer Erle Mast at the Credit Suisse Healthcare conference on Nov. 12. Mast

Celgene Corp. deepened its commitment to both epigenetics and multiple myeloma with a $100 million payment to five-year-old Acetylon Pharmaceuticals Inc. , giving it an option to acquire the priv